$2 million federal grant to study cancer drug action

October 22, 2002

ITHACA, N.Y. -- Gene Network Sciences (GNS), a fledgling cancer-research company started by Cornell University graduate students and financed by Cornell business students, has been awarded a $2 million federal Advanced Technology Program (ATP) grant. ATP is administered by the National Institute of Standards and Technology and makes annual grants that are matched by industry.

GNS was founded two years ago, and just 10 months ago it received funding of $125,000 from the Cornell Big Red Venture Fund, a venture capital group operated by students of Cornell's S.C. Johnson Graduate School of Management. The investment was the fund's first in biotechnology.

Scientists at GNS will use the new federal grant to learn how pharmaceuticals work against parts of cancer cells. "We've mapped the cell pathways, and we have created the world's largest computer simulation of a human cancer cell. However, we need to generate more biological data to confirm how our simulation works. This grant helps pay for that research," says co-founder Colin Hill, a Cornell doctoral candidate in physics. GNS co-founder Iya Khalil obtained her doctorate at Cornell in 2001.

Two Cornell faculty members will advise in the research: Richard A. Cerione, professor of molecular medicine at the College of Veterinary Medicine, and Steven Strogatz, professor of theoretical and applied mechanics, sit on the company's scientific advisory board. Bruce Ganem, professor of chemistry and chemical biology, is a company consultant.

Hill said the grant would provide enough money to hire five to seven more researchers to perform micro-array and proteomics experiments.

During the three-year project, researchers will process large quantities of new data with new and existing proprietary software to create computer models, or simulations, of normal and cancerous cells as a means of rapidly identifying nontoxic drug targets. Using the company's existing 500-component cell model and simulation tools as a basis, GNS will simulate detailed models of cells incorporating up to 2,000 components.Hill believes the company's research program will make the drug-discovery process -- often considered haphazard and full of educated guesswork -- more predictable for pharmaceutical and biotech companies. "This is the new technology that will revolutionize pharmaceutical drug discovery," he says.

This is GNS's second federal award. In September the company received a $100,000 Small Business Innovation research grant from the National Institutes of Health to model key colon cancer signaling pathways and to test the predictions of the company's cell computer simulations.

The GNS ATP award was one of 40, totaling $101.6 million, granted by the program in the 2002 annual competition. The awards will be matched by industry cost-sharing of $92 million if carried through to completion. GNS was one of three New York state companies receiving the awards.

The ATP program bridges the gap between the research lab and the marketplace by stimulating innovation through partnerships with the private sector. ATP's early stage investment accelerates the development of innovative technologies that promise significant commercial payoffs.
-end-
Related World Wide Web sites: The following site provides additional information.

  • Gene Network Sciences: http://www.gnsbiotech.com/

    Cornell University

    Related Cancer Cells Articles from Brightsurf:

    Cancer researchers train white blood cells to attacks tumor cells
    Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

    New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
    Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

    Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
    According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

    Breast cancer cells turn killer immune cells into allies
    Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

    Breast cancer cells can reprogram immune cells to assist in metastasis
    Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

    Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
    CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

    Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
    A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

    Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
    In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

    First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
    Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

    Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
    Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

    Read More: Cancer Cells News and Cancer Cells Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.